Back

Macitentan tadalafil Fixed Dose Combination (FDC) in treatment-naive and prior monotherapy patients with Pulmonary Arterial Hypertension (PAH): insights from A DUE

27 August 2023 (16:15 - 17:00)
Organised by: Logo
Congress Presentation Part of: Current treatment of pulmonary hypertension: it is all about vasodilators Pulmonary Hypertension ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Professor Pavel Jansa

First Faculty of Medicine and General Teaching Hospital, Prague (Czechia)

7 More presentations in this session

Presentation thumbnail
Effect of a short course of parenteral treprostinil therapy on right heart structure and function in pulmonary arterial hypertension
Doctor C. Vizza (Rome, IT)
Abstract Slides Video
Presentation thumbnail
Triple therapy for incident pulmonary arterial hypertension in Finland between 2008 and 2020. A descriptive real-world FINPAH cohort study
Doctor M. Pentikainen (Helsinki, FI)
Abstract Slides Video
Presentation thumbnail
The effect of sildenafil on maternal mortality in pulmonary arterial hypertension associated with congenital heart disease
Doctor N. Nahdi (Yogyakarta, ID)
Abstract Slides Video
Presentation thumbnail
Efficacy comparison of prostacyclin analogue and prostacyclin receptor agonist as third line treatment for pulmonary arterial hypertension
Doctor G. martini (Bologna, IT)
Abstract Slides Video
Presentation thumbnail
Specific therapies of pulmonary hypertension and prognosis in COVID-19: 18-months analysis of BNP-PL national database.
Doctor A. Mamzer (Lodz, PL)
Abstract Slides Video

Access the full session

Session thumbnail
Current treatment of pulmonary hypertension: it is all about vasodilators

The Event

Event poster

ESC Congress 2023

27 August 2023 16:15 CET
You may be interested in
thumbnail
Congress Presentation
Safety and efficacy of macitentan and riociguat upfront combination therapy in patients with idiopathic pulmonary arterial hypertension at intermediate risk.
thumbnail
Congress Presentation
Efficacy and tolerability of triple sequential combination therapies with selexipag in patients with pulmonary arterial hypertension : insights from a single-centre study
thumbnail
Congress Presentation
Hemodynamic changes with pulmonary arterial hypertension targeted therapies: a meta-analysis of 3898 treatment-naive patients

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources